Kestra Medical (KMTS) Q3 2024 Earnings Report

Kestra Medical Technologies Ltd (KMTS) reported QQ3 2024 revenue of $15.09 million with a Gross Profit of $6.55 million and a gross margin of 43.39%. Despite the revenue expansion relative to the prior-year quarter, the company posted a substantial operating loss of $20.60 million and a net loss of $21.51 million for the quarter, driven by high operating expenses (SG&A and R&D) that outweighed the gross margin gains. EBITDA was negative $18.07 million. Management commentary is not available in the provided data set, and no earnings-call transcript was supplied, limiting direct quotes from executives to anchor forward-looking statements. The quarterly cash burn is evident: operating cash flow was negative $18.38 million, with capex of $4.06 million, producing a free cash flow of negative $22.45 million. The company closed QQ3 2024 with approximately $54.69 million in cash, cash equivalents, and restricted cash, signaling a short-term liquidity runway absent material financing or a near-term acceleration in revenue and/or margin improvement. The contrast between top-line growth and persistent losses suggests the business is in an investment phase, focusing on driver themes like platform adoption, R&D intensity, and go-to-market expansion, while needing a clear path to sustained profitability. Investors should monitor operating expense discipline, the trajectory of Cardiac Recovery System (ASSURE WCD) adoption, reimbursement dynamics, and potential capital needs going forward.